Integer Holdings Conference Call Summary Company Overview - **Company**: Integer Holdings (NYSE: ITGR) - **Date**: March 18, 2026 - **Participants**: Payman Khales (CEO), Diron Smith (CFO), Kristen Stewart (Investor Relations) Key Points Management Transition - The transition to the new CEO has been smooth, with a strong foundation and strategy in place [3][4] - Focus areas include customer success, operational excellence, and talent development [4] Board of Directors and Governance - A cooperation agreement was reached with Irenic Capital Management, resulting in the addition of two new board members [6][7] - The board refreshment process has been ongoing, with five new members added in the last five years [6] 2026 Guidance and Market Performance - 2026 is viewed as a transition year with expected headwinds from three products that had strong growth in 2025 but are not meeting adoption expectations [10][11] - These three products contributed just under 6% of total revenues in 2025, but are expected to drop below 2% in 2026, resulting in a headwind of 300-400 basis points [13][14] - The underlying business is expected to grow at a rate of 4%-6% excluding the impact of these products [10][22] Market Growth Expectations - The company anticipates a return to market growth in the second half of 2026, with expectations of achieving 200 basis points above market growth in 2027 [12][26] - The growth rate is supported by a strong pipeline and new product launches in faster-growing markets such as neurovascular, structural heart, and electrophysiology [16][18] Margin and Cost Management - Operating margins are expected to experience pressure in Q1 2026 due to fixed cost deleveraging but are projected to improve throughout the year [28][29] - The company is focused on disciplined cost management and expects to leverage fixed costs as sales grow [28][30] Input Cost Volatility - The company does not foresee significant impacts from recent volatility in input costs, as a large portion of the supply base is in the US and there are price protections in place [32][34] Long-term Financial Objectives - Strategic financial objectives remain unchanged: to grow sales 200 basis points above market and to grow operating income at twice the rate of sales growth [36][37] Product Development and Pipeline - Product development sales have quadrupled since 2017, indicating a strong pipeline and customer relationships [50][51] - The PMA product portfolio is expected to grow at a CAGR of 15%-20% over the next 3-5 years [53] Capacity Expansion - The company is strategically expanding its capacity to avoid constraints on growth, with recent expansions in facilities in Ireland and Virginia [55][56] Market Positioning - Integer is well-positioned in the electrophysiology market, with a broad portfolio and strong pipeline [39][40] - Neuromodulation is expected to grow at a high single-digit rate, with various therapies addressing multiple conditions [61][62] Future Growth Opportunities - Renal denervation is viewed as a potential long-term growth opportunity, leveraging existing capabilities in electrophysiology [64] Conclusion - Integer Holdings is navigating through a transition year with temporary headwinds but remains optimistic about returning to growth in the latter half of 2026 and achieving above-market performance in 2027 and beyond [67]

Financial Data and Key Metrics Changes - Fourth quarter sales reached $2.7 billion, representing a 7% increase year-over-year [18] - Core gross margin was 62.5%, down 50 basis points year-over-year, primarily due to incremental tariffs [20] - Core diluted earnings per share were $0.78 for the quarter [21] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 6% year-over-year to $1.5 billion, with implantable sales at $474 million, up 2% [18] - Vision Care sales were $1.2 billion, up 7%, with contact lens sales increasing by 4% to $683 million [19] - Ocular Health sales reached $474 million, up 12%, driven by strong performance in the dry eye portfolio, including Tryptyr and Systane [19] Market Data and Key Metrics Changes - Global cataract procedural volumes grew approximately 3% in the fourth quarter [17] - The global contact lens market grew approximately 4%, primarily driven by strength in the U.S. market [17] Company Strategy and Development Direction - The company is focused on innovation, with multiple product launches expected to drive growth, including the Unity VCS and CS platforms [8][9] - The company aims to expand its IOL portfolio with new products like PanOptix Pro and TruPlus, enhancing its competitive position [10][11] - The company is committed to optimizing its cost structure and supporting long-term margin expansion through efficiency measures [24] Management's Comments on Operating Environment and Future Outlook - Management noted that while the markets showed improvement in the fourth quarter, they are not yet back to normal [32] - The outlook for 2026 assumes aggregate eye care market growth of 3%-4%, with top-line growth expected between 5% and 7% [22][23] - Management expressed confidence in sustaining a healthy double-digit growth rate in equipment sales due to strong demand for Unity products [39] Other Important Information - The company generated $1.7 billion of free cash flow in 2025, compared to $1.6 billion in 2024, enabling significant shareholder returns [21] - The board proposed a dividend of 28 Swiss centimes per share, aligning with the payout policy of approximately 10% of the previous year's core net income [25] Q&A Session Summary Question: Guidance visibility and market conditions - Management indicated that markets improved in the fourth quarter but are not yet back to normal, maintaining a balanced view for the upcoming year [32][33] Question: Equipment growth contribution from Unity - Unity significantly contributed to equipment growth, with strong demand and positive feedback from customers [39] Question: Tryptyr sales tracking and future expectations - Tryptyr is performing well, with management comfortable with peak sales estimates of $250 million to $400 million [41][42] Question: IOL market dynamics and growth expectations - The U.S. IOL market showed solid performance, with PanOptix Pro leading the way, while international markets faced more competition [52][54] Question: Surgeon capacity in the U.S. cataract market - Management noted that surgeon productivity is improving, with practices finding ways to increase surgery days [75][76] Question: Margin guidance and new product impact - Management expects continued price increases and leverage from new product launches to support margin improvement [78]

Financial Data and Key Metrics Changes - Fourth quarter sales reached $2.7 billion, representing a 7% increase year-over-year [18] - Core gross margin was 62.5%, down 50 basis points from the previous year, primarily due to incremental tariffs [20] - Core diluted earnings per share were $0.78 for the quarter [21] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 6% year-over-year to $1.5 billion, with implantable sales at $474 million, up 2% [18] - Vision Care sales were $1.2 billion, up 7%, with contact lens sales increasing by 4% to $683 million [19] - Ocular Health sales reached $474 million, up 12%, driven by strong performance in the dry eye portfolio, including Tryptyr and Systane [20] Market Data and Key Metrics Changes - Global cataract procedural volumes grew approximately 3% in the fourth quarter [17] - The global contact lens market grew approximately 4%, primarily driven by strength in the U.S. market [17] Company Strategy and Development Direction - The company is focused on innovation, with multiple product launches expected to drive growth, including the Unity VCS and CS platforms [9][10] - The company aims to expand its IOL portfolio with new lenses like PanOptix Pro and TruPlus, enhancing its competitive position [11][12] - The company is committed to optimizing its cost structure and supporting long-term margin expansion through efficiency measures [24] Management's Comments on Operating Environment and Future Outlook - Management noted that while the markets showed improvement in the fourth quarter, they are not yet back to normal [32] - The company expects aggregate eye care markets to grow 3%-4% for the year, with top-line growth projected between 5% and 7% [22][23] - Management expressed confidence in sustaining a healthy double-digit growth rate in equipment as they enter 2026 [45] Other Important Information - The company generated $1.7 billion of free cash flow in 2025, compared to $1.6 billion in 2024, enabling significant shareholder returns [21] - The board proposed a dividend of 28 Swiss centimes per share, aligning with the payout policy of approximately 10% of the previous year's core net income [25] Q&A Session Summary Question: Guidance visibility and revenue growth expectations - Management indicated that the markets improved in the fourth quarter and expects a balanced view of market conditions for the upcoming year [32][34] Question: Contribution of Unity to equipment growth - Management confirmed that Unity significantly contributed to equipment growth, with strong demand and positive feedback from customers [38] Question: Tryptyr sales tracking and future expectations - Management expressed confidence in Tryptyr's performance, indicating it is tracking ahead of expectations and may reach the higher end of the previously stated peak sales range [41] Question: IOL market dynamics and future product launches - Management noted strong performance in the U.S. IOL market, with upcoming product launches expected to enhance competitive positioning [52][68] Question: U.S. surgeon capacity in the cataract market - Management highlighted that surgeon productivity is improving, with practices finding ways to increase surgery days and manage demand effectively [72][76] Question: Margin guidance and new product impact - Management indicated that new product launches and pricing will contribute positively to margins, alongside ongoing cost-saving initiatives [78]

Core Insights - Allegion plc reported strong enterprise revenue growth driven by robust performance in the Americas nonresidential markets and over $600 million in accretive M&A [5] - The company experienced underperformance in U.S. residential markets in Q4, with volume declines offsetting favorable price realization [5] - Management expects continued margin expansion due to pricing and productivity gains that exceed inflationary impacts [5] Strategic Performance Drivers - Americas nonresidential markets benefited from healthy demand and robust spec-writing trends, providing resilience amid macro volatility [5] - International segment growth was primarily fueled by Electronics and M&A, which mitigated sluggishness in Mechanical markets [5] - The company expanded its mid-tier commercial portfolio with new product launches to capture broader market share in the nonresidential aftermarket [5] 2026 Outlook and Strategic Assumptions - The 2026 guidance assumes Americas nonresidential volume growth remains consistent with 2025 levels, supported by current specification activity [5] - Management projects soft demand in the Americas residential segment throughout 2026, with a slight decline expected for the year [5] - Organic growth in the Americas segment is anticipated to rely more on pricing than volume [5] Capital Allocation and Risk Factors - Allegion deployed approximately $630 million toward acquisitions in 2025, focusing on core mechanical, electronics, and software solutions [5] - The company increased its dividend for the twelfth consecutive year, indicating a commitment to balanced capital return alongside growth investments [5] - Net debt to adjusted EBITDA stands at 1.6 times, providing significant balance sheet flexibility for continued disciplined M&A [6]

Financial Data and Key Metrics Changes - The company reported a strong fourth quarter and full-year performance, with non-GAAP diluted EPS of $1.99 for Q4 and $15.28 for the full year 2025, exceeding expectations [26][35] - Total revenue for the full year 2025 was $9.9 billion, up 2% compared to 2024, with growth products generating $3.3 billion, a 19% increase [4][28] - Free cash flow for the year was $2.1 billion, with cash and marketable securities totaling $4.2 billion at year-end [28][33] Business Line Data and Key Metrics Changes - Growth products generated over $800 million in Q4 2025, up 6% year-over-year, and $3.3 billion for the full year, up 9% [27] - Leqembi saw fourth quarter in-market sales of approximately $134 million, up 10% sequentially and 54% year-over-year [29] - Spinraza revenue in Q4 was $356 million, with U.S. revenue of $169 million, showing resilience despite a competitive market [30] Market Data and Key Metrics Changes - The U.S. MS business generated total revenue of $9.9 billion for the full year 2025, reflecting a 2% increase from 2024 [28] - Leqembi maintained over 60% market share in the anti-amyloid therapy market, indicating strong competitive positioning [8] - The market for anti-amyloid therapy has more than doubled, with increasing physician reports of patient benefits [11] Company Strategy and Development Direction - The company is focusing on growth through new medicines, with a pipeline that includes several first-in-class treatments [12][22] - Strategic investments are being made in pre-launch activities for lupus and nephrology products, with a focus on maintaining financial discipline [34][35] - The company aims to build a bridge to growth by expanding its early-stage pipeline and pursuing business development opportunities [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth of the company, particularly with expected approvals for key products like Leqembi and Litifilimab [18][25] - The company anticipates a decline in total revenue by a mid-single-digit percentage for 2026, primarily due to competitive pressures in the MS market [36] - Management highlighted the importance of upcoming phase 3 data readouts for Litifilimab and Felzartamab, which could significantly impact future growth [19][25] Other Important Information - The company has secured priority review for Leqembi and received breakthrough therapy designation for Litifilimab, indicating strong external recognition of its pipeline [21][24] - The company is actively pursuing collaborations and business development opportunities to enhance its pipeline and market position [6][8] Q&A Session Summary Question: Can you walk us through the cadence of Leqembi sales growth this year? - Management indicated a persistency rate of about 70% for patients transitioning to maintenance therapy, with expectations for continued sequential growth [39][40] Question: When do you think Biogen's top line could return to growth? - Management noted that growth products have outstripped declines in the MS portfolio, but positive phase 3 results and potential acquisitions are crucial for returning to growth [45][46] Question: How important is the upcoming BIIB080 data? - Management emphasized the significance of the data, noting that the neurology community is closely watching the potential impact of tau reduction on cognition [52][53] Question: What is the conviction level for Litifilimab's phase 3 trials? - Management expressed high conviction in Litifilimab due to its targeting of the BDCA2 pathway and previous positive data from earlier studies [63][64] Question: How important is it to hit the eGFR endpoint for Felzartamab? - Management acknowledged the importance of the eGFR endpoint while focusing on the primary endpoint, with ongoing evaluations for broader applications in other transplants [68][70]

Summary of Weitai Medical Conference Call Company Overview - **Company**: Weitai Medical - **Industry**: Continuous Glucose Monitoring (CGM) Devices Key Points Industry and Market Performance - Weitai Medical's CGM device shipments and user numbers have increased significantly, with shipments up over 600% and user numbers up nearly 300% year-on-year, ranking first in the CGM category on Tmall [2][3] - The international business growth rate is significantly higher than the company's average, particularly in emerging markets such as Asia-Pacific, Latin America, and Africa, with market share and brand influence improving through participation in large tenders and the establishment of medical insurance service systems [2][4] Financial Performance and Projections - The company achieved a revenue growth target of at least 40% for 2025, with CGM category growth expected to be double that of the overall company growth [5] - The CGM gross margin remains stable, with cost reductions of approximately 10-20% achieved through supply chain optimization and automated production lines [2][11] - The company anticipates clear profit growth in 2026, following its first profitable year in 2025 [5][21] Patent Litigation and Strategy - Weitai Medical is actively responding to Abbott's patent litigation, asserting that the validity of the disputed 072 patent is unstable and preparing new design strategies to circumvent potential risks [2][6] - The impact of the patent dispute on the European market is limited, as sales in that region account for less than 5% of international CGM sales [6][7] Product Development and Innovation - The company plans to enhance investment in overseas markets, clinical support personnel, and backend R&D, particularly in core positions related to structure, software, and algorithms [5] - New product designs, including a next-generation split CGM, are set to optimize the product portfolio [5][12] Sales and Marketing Strategy - Weitai Medical's pricing strategy positions its CGM products 20-30% lower than Abbott's, while maintaining a similar gross margin [2][12] - The company has seen significant online sales growth, particularly on platforms like Tmall and Xiaohongshu, with a focus on enhancing brand competitiveness through targeted marketing strategies [17] Challenges and Competitive Landscape - The competitive landscape in regions like Latin America and Southeast Asia is relatively less intense, with fewer competitors compared to the domestic market [10] - The company is prepared for potential challenges in the European market, including software and compound-related disputes, and has strategies in place to address these risks [7][10] Future Outlook - Weitai Medical's core products focus on CGM and closed-loop insulin pump systems, with expectations for significant contributions to revenue growth from these innovations [19] - The company aims to establish a stronger product portfolio targeting both domestic and international markets, with a focus on cost reduction and technological advancements [20] Miscellaneous - The recent share sale by the actual controller was due to tax considerations, not a personal reduction in holdings [2][8] - The company does not anticipate needing to undergo new clinical approval processes for product design changes, as these do not involve material changes [16] This summary encapsulates the key insights from Weitai Medical's conference call, highlighting the company's strong market performance, strategic initiatives, and future growth prospects.

Summary of Ampco-Pittsburgh Conference Call Company Overview - **Company Name**: Ampco-Pittsburgh Corporation - **Founded**: 1929 - **Employees**: Approximately 1,500 - **Annual Revenue**: Over $400 million - **Market Capitalization**: Over $50 million - **Segments**: - Forging, Casting, and Product Segment - Air and Liquid Processing Segment - **Market Position**: - Number one in North America and Europe for forging and casting products - Number one in North America for heat exchangers in nuclear power plants [2][3] Core Business Insights - **Strategic Focus**: - Exit unprofitable assets, resulting in improved EBITDA from $78 million to a stronger position [3] - Growth in Air and Liquid Processing and operational efficiencies [3] - **Market Presence**: - 90% of nuclear power plants in North America utilize their products [3] - Leading producer of pumps for the U.S. military [3] Segment Analysis Forging, Casting, and Product Segment - **Sales Distribution**: 70% of sales in North America and Europe [4] - **Product Types**: - Backup rolls, work rolls, and forged engineered products [4] - 90% of sales are rolls, with a market size of approximately $2 billion [8] - **Tariff Impact**: - Tariffs increased from 25% to 50%, creating barriers for imports and benefiting domestic sales [5][9] - **Competitors**: - Major competitors include Lehigh Heavy Forge, Superior Steel, and Villares [9] - **Market Growth**: - Anticipated growth in steel and aluminum markets will increase demand for rolls [7][13] Air and Liquid Processing Segment - **Key Businesses**: - Aerofin (custom heat exchangers), Buffalo Air Handling (air handling units), Buffalo Pumps (custom pumps) [15] - **Market Growth**: - 55% revenue growth over the last three years, with significant barriers to entry [16][17] - **Key Customers**: - Major clients include Eli Lilly, Merck, Johnson & Johnson, and the U.S. Navy [15][16] - **Nuclear Market**: - Growth driven by the restart of nuclear plants and the emergence of small modular reactors [19] Financial Performance - **Recent Developments**: - Exited underperforming businesses, including a facility in the U.K. [23] - Anticipated increase in adjusted EBITDA by $7-8 million due to the exit of underperforming assets [24] - **Balance Sheet Improvements**: - U.S. pension plan nearing 100% funding, with a roadmap to reduce leverage from 4.0 to 3.0 [26][27] - **Future Projections**: - Expected continued growth in adjusted EBITDA and margins [24][29] Market Trends and Opportunities - **European Market Changes**: - Europe is reducing import quotas and increasing tariffs, which will benefit Ampco-Pittsburgh [12][13] - **End Market Growth**: - Mid-single-digit growth projected in key end markets over the next five years [13] - **International Expansion**: - Active steps to expand into markets outside North America, including partnerships in Australia [38] Additional Insights - **Operational Efficiency**: - Investment of approximately $30 million in equipment modernization to enhance reliability and efficiency [11] - **Customer Base**: - Top 10 customers account for roughly half of revenue, indicating a concentrated customer base [10] - **Margin Improvements**: - Recent pricing increases in the U.S. market for forged rolls, with margins improving significantly [39] This summary encapsulates the key points discussed during the conference call, highlighting Ampco-Pittsburgh's strategic direction, market position, financial performance, and growth opportunities.

Group 1 - The core growth for the company in the U.S. market next year is expected to come from the launch of home furniture products after the shift from Southeast Asia [1] - Continuous optimization in operations, including VC and warehousing logistics, is anticipated to support the ongoing recovery of profitability in the U.S. [1]

Financial Data and Key Metrics Changes - The company reported a 11% organic sales growth year-over-year and a 16% increase in EBITDA to $122 million, with margins expanding by 120 basis points to 26.8% [4][10] - Free cash flow for the quarter was $94 million, and the company repurchased approximately 600,000 shares, totaling $135 million year-to-date, representing about 3.8% of total shares outstanding [4][11] - The company raised its dividend by 22% and refreshed its share buyback program to $500 million [4] Business Line Data and Key Metrics Changes - Sales totaled $455 million in the third quarter, reflecting 11% core growth year-over-year, with the non-residential market remaining positive while the residential market showed softness [9] - The company experienced a full quarter impact from tariff-related price increases implemented in April, contributing to the core growth [9][10] Market Data and Key Metrics Changes - The company anticipates that the market outlook for 2026 will resemble that of 2025, with an acceleration in growth pushed to 2027 due to uncertainties around tariffs and interest rates [5][6] - Key macro indicators such as the Dodge Momentum Index, Architectural Billing Index, and Construction Backlogs are monitored to assess future construction spending [16][19] Company Strategy and Development Direction - The company is focused on leveraging internal growth initiatives and competitive advantages, including product portfolio breadth and unique market positioning [6][30] - There is an intention to sharpen focus on driving organic growth into adjacent categories, supported by a strong cash flow generation and low leverage [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining price-cost positivity despite tariff impacts, projecting year-over-year core sales growth in the high single digits for the fourth quarter [32][33] - The company expects adjusted EBITDA margins to remain strong, with a new baseline established for future performance [64] Other Important Information - The company completed its U.S. pension plan termination, eliminating approximately $200 million in liabilities and related assets [11][12] - The company has maintained a strong track record of growth, with 55 out of the last 59 quarters showing year-over-year quarterly growth [26] Q&A Session Summary Question: Has there been any meaningful divergence in growth rates across legacy Zurn product categories over Q3 or into Q4? - Management indicated that most core categories are experiencing solid unit growth, with no significant changes expected as they head into the fourth quarter [38] Question: Can you provide an update on the reception of Elkay Pro Filtration and the market opportunity with the LIV EZ line? - Management reported strong uptake for the Elkay Pro Filtration system and expressed excitement about the LIV EZ product as a market extension, though not a primary growth pillar [40][41] Question: How should volume expectations be considered for the back half of the year? - Management noted good volume growth in Q3, with expectations for similar momentum in Q4, despite some pull forward in orders due to a price increase [46][47] Question: What are the priorities for capital allocation going forward? - Management reiterated a focus on reducing leverage, investing in core business, and maintaining a steady approach to share repurchases and dividends [52] Question: Can you provide insights on the M&A funnel and its evolution over the last 12 months? - Management stated that while the funnel has not changed significantly, there are more opportunities at the top, and they continue to evaluate various M&A prospects [58] Question: How do you view the consistent strong margin results and future expectations? - Management expressed confidence that the current margin levels represent a new baseline, with expectations for continued margin expansion driven by operational efficiencies [64]

Core Insights - The Greater China region has become the largest market for Amer Sports, with a significant revenue increase of 42% year-on-year in Q2, reaching $410 million (approximately 2.92 billion RMB) [5][9] - The brand Arc'teryx is identified as a key growth driver for Amer Sports, contributing to the overall performance of the company [5][9] Financial Performance - In Q2, Amer Sports' revenue from the Greater China region grew to $410 million, while EMEA and North America saw growth rates of 18.5% and 6.3%, respectively [5] - The Technical Apparel segment, which includes Arc'teryx, reported a 23% increase in revenue to $510 million, while Outdoor Performance and Ball & Racquet segments also showed positive growth [5][6] Market Dynamics - The competitive landscape in the Chinese sports market is intensifying, with local brands like Anta and Li-Ning rapidly gaining market share [10][12] - The outdoor sports market in China is becoming a focal point for competition, with major brands like Nike increasing their focus on this segment [14] Management Changes - Ivan She, the General Manager of Arc'teryx Greater China, has left the company, and Jeffery Ma is currently acting in this role [2][3] - This marks the second executive change in the Greater China region within a year, indicating potential instability in leadership [2][3] Strategic Challenges - The high-end market, where Arc'teryx operates, is facing challenges, with luxury brands reporting mixed performance in China [13] - Amer Sports anticipates a net store closure for Arc'teryx in China by 2025, reflecting the need for strategic adjustments in response to market conditions [15][16] Consumer Behavior - Recent sales data indicates a decline in Arc'teryx's visibility in the Chinese market, as it did not appear on the Tmall Double 11 outdoor sales leaderboard, contrasting sharply with its previous performance [17][18]